Expanding the Applications of Treg Therapies into a Clinical Reality

Accelerating Clinically Differentiated Treg & Treg-Modulating Therapies to Deliver Durable Immune Tolerance in Autoimmune, Inflammatory, & Neurodegenerative Disease

The regulatory T-cell field is entering an important new phase. As teams from Quell Therapeutics, GentiBio, and Orca Bio generate increasingly compelling clinical data across autoimmune, inflammatory, and transplant indications, the conversation is shifting from scientific promise to clinical differentiation, scalability, and long-term commercial success.

Returning to Boston, the 9th Treg-Directed Therapies Summit remains the industry's longest-running and most established meeting dedicated exclusively to Treg-directed therapies. Bringing together developers working across engineered Tregs, CAR-Tregs, and in vivo Treg-modulating approaches, the summit provides a unique opportunity to benchmark progress, learn from emerging clinical and translational data, and connect with the organizations shaping the future of immune tolerance.

Download the Agenda

Great conference. The agenda was very good and there was a good level of breaks to enable interaction with other attendees. Best Treg Summit I've been at in a while.

GentiBio, 2026 Speaker

Gentibio testimonial highlighting the value of attending the 9th Treg-Directed Therapies Summit, with feedback on networking, scientific discussions, and industry collaboration.

Comprehensive gathering of Treg experts across academia and industry.

Johnson & Johnson, 2026 Attendee

Johnson & Johnson testimonial highlighting key insights, strategic discussions, and networking opportunities at the 9th Treg-Directed Therapies Summit.

I really enjoyed that this is a small conference with leaders in the field that fosters getting to know each other. The science was also excellent.

Stanford University, 2026 Speaker

Stanford University testimonial highlighting scientific insights, collaboration opportunities, and key takeaways from the 9th Treg-Directed Therapies Summit.

It was great to know what the top companies were thinking and doing, and their belief that Treg therapy would definitely work. The future is happening.

Medicover Hospital, 2026 Attendee

Medicover Hospitals testimonial highlighting key learnings, expert discussions, and networking opportunities at the 9th Treg-Directed Therapies Summit.

New for 2027: World Immune Tolerance Week

For the very first time, the 9th Treg-Directed Therapies Summit is becoming part of World Immune Tolerance Week alongside the 10th Antigen-Specific Immune Tolerance Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit to bring together the full autoimmune and immunology disease community. While each summit retains its own scientific focus, expert speaker faculty, and community, attendees will gain access to all three meetings, enabling cross-disciplinary learning, richer networking, and collaboration across antigen-specific therapies, Treg approaches, B-cell modulation, and broader immune resetting strategies.